FEASIBILITY, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTFeasibility, Development and Commercialization Agreement • May 27th, 2010 • Auto Search Cars, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 27th, 2010 Company Industry JurisdictionThis Feasibility, Development and Commercialization Agreement (this “Agreement”) is made as of July 22, 2002, by and between Voyager Pharmaceutical Corporation, a Delaware corporation with its principal place of business at 8540 Colonnade Center Drive, Raleigh, NC 27615 (“Voyager”), and Southern Biosystems, Inc., an Alabama corporation with its principal place of business at 756 Tom Martin Drive, Birmingham, Alabama 35211 (“SBS”).
SUPPLY AGREEMENTSupply Agreement • May 27th, 2010 • Auto Search Cars, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 27th, 2010 Company Industry JurisdictionThis Agreement (this "Agreement") is made effective as of this 1st day of January, 2009 between ,Voyager, Inc., 8540 Colonnade Center Drive, Suite 490, Raleigh, North Carolina 23615 ("Voyager") and Mallincicrodt Inc., 675 McDonnell Blvd., Hazelwood, Missouri 63042 ("Mallinckrodt").
AMENDMENT NO. 1 TO FEASIBILITY, DEVELOPMENT AND COMMERCIALIZATION AGREEMENTFeasibility, Development and Commercialization Agreement • May 27th, 2010 • Auto Search Cars, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledMay 27th, 2010 Company Industry JurisdictionThis Amendment No. 1 to Feasibility, Development And Commercialization Agreement ("Amendment No. 1") is entered into effective January 23, 2007 (the "Amendment Date") by and between DURECT Corporation ("DURECT") and Voyager Pharmaceutical Corporation ("Voyager").
INVESTOR DEVELOPMENT & CORPORATE IMAGING AGREEMENTInvestor Development & Corporate Imaging Agreement • May 27th, 2010 • Auto Search Cars, Inc. • Pharmaceutical preparations • New York
Contract Type FiledMay 27th, 2010 Company Industry JurisdictionThis Investor Development and Corporate Imaging Agreement ("Agreement") is made as of the day of , 2009 ("Effective Date") by and between GroupMark Financial Services Ltd, a Hong Kong corporation (the "Investor Development Manager"), and Voyager Pharmaceutical Corporation (the "Company"), a Delaware Corporation.